Clinical trial
Lapatinib and Bevacizumab for Metastatic Breast Cancer
NCT00444535 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00444535 |
|---|---|
| Title | Lapatinib and Bevacizumab for Metastatic Breast Cancer |
| Official title | A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib, bevacizumab |
| Enrollment | 52 |
| Start date | Feb 27, 2007 |
| Primary completion | Jul 22, 2008 |
| Completion | Jun 19, 2020 |
| First posted | Mar 8, 2007 |
| Last update posted | Oct 25, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: